| Date Filed | Type | Description |
| 10/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/11/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/02/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 09/28/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/04/2023 |
3
| GARDINER SANDRA A. (Acting CFO) has filed a Form 3 on Anebulo Pharmaceuticals, Inc. |
| 03/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"MASTER SERVICES AGREEMENT This Master Services Agreement is made effective as of March 2, 2023 , by and between Anebulo Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business being 1415 Ranch Road 620 South, Suite 201, Lakeway, TX 78734 and Potrero Hill Advisors, LLC., a California limited liability corporation, with its principal place of business being 2010 El Camino Real #1311, Santa Clara, CA 95050 . The Company and Potrero are herein sometimes referred to individually as a “Party” and collectively as the “Parties.” WHEREAS, the Company wishes to engage Potrero to serve as an independent consultant for the purpose of providing the Company with certain strategic and financial advice and support services, as more fully described in Exhibit A attached hereto ;..." |
|
| 02/10/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 02/10/2023 |
8-K
| Quarterly results |
| 01/09/2023 |
8-K
| Investor presentation |
| 12/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/02/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 11/02/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 10/28/2022 |
8-K
| Quarterly results |
| 10/25/2022 |
DEFR14A
| Form DEFR14A - Revised definitive proxy soliciting materials: |
| 10/17/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/13/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 10/04/2022 |
4
| Lawler Joseph F. (10% Owner) has filed a Form 4 on Anebulo Pharmaceuticals, Inc.|
Txns:
| Granted 30,425 options to buy
@ $6, valued at
$182.6k
|
|
| 10/04/2022 |
4
| Lin Kenneth (Director) has filed a Form 4 on Anebulo Pharmaceuticals, Inc.|
Txns:
| Granted 30,425 options to buy
@ $6, valued at
$182.6k
|
|
| 10/03/2022 |
4
| Parschauer Karah Herdman (Director) has filed a Form 4 on Anebulo Pharmaceuticals, Inc.|
Txns:
| Granted 30,425 options to buy
@ $6, valued at
$182.6k
|
|
| 10/03/2022 |
4
| Aryeh Jason (Director) has filed a Form 4 on Anebulo Pharmaceuticals, Inc.|
Txns:
| Granted 30,425 options to buy
@ $6, valued at
$182.6k
|
|
| 10/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/03/2022 |
4
| ALLEN SIMON (CEO) has filed a Form 4 on Anebulo Pharmaceuticals, Inc.|
Txns:
| Granted 77,457 options to buy
@ $7.02, valued at
$543.7k
|
|
| 09/30/2022 |
4
| English Aron R. (10% Owner) has filed a Form 4 on Anebulo Pharmaceuticals, Inc.|
Txns:
| Granted 1,703,577 shares
@ $2.81, valued at
$4.8M
Granted 30,425 options to buy
@ $6, valued at
$182.6k
Granted 1,703,577 options to buy
@ $4.215, valued at
$7.2M
|
|
| 09/29/2022 |
8-K
| Quarterly results |
| 09/26/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 09/09/2022 |
10-K
| Annual Report for the period ended June 30, 2022 |
| 09/09/2022 |
8-K
| Quarterly results |
|